Basel, 27 December 2018: The Straumann Group and Nobel Biocare have settled their long-running patent dispute in the USA. The dispute began in 2014 and involved an early version of the Neodent Drive CM implant, which was superceded soon afterwards. Nobel Biocare claimed that the version in question infringed two of its patents but Straumann successfully challenged one of them at the US Patent Trial and Appeal Board. The ruling, which invalidated a patent on a key feature of the NobelActive® implant, was recently upheld – despite Nobel Biocare’s subsequent appeal to the the US Court of Appeals for the Federal Circuit. Nobel Biocare has now agreed to take no further action regarding the decision and to dismiss its pending court action.
“We are delighted with this outcome” said Dr Andreas Meier, General Counsel of the Straumann Group. “Neodent’s new GM implant range is unchallenged and we are not required to pay any compensation”.
The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Straumann, Neodent, Medentika, ClearCorrect, Dental Wings, and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, biomaterials and digital solutions for use in tooth replacement and restoration or to prevent tooth loss.
Headquartered in Basel, Switzerland, the Group currently employs approx. 5700 people worldwide and its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.